文献速递食管胃疾病与幽门螺杆菌消化内镜

磁括约肌增强术在1年随机试验中优于质子泵抑制剂控制反流

Magnetic Sphincter Augmentation Superior to Proton Pump Inhibitors for Regurgitation in a 1-Year Randomized Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-09-10

该随机试验纳入152例每日一次PPI仍中重度反流的GERD患者,比较每日两次PPI与腹腔镜磁括约肌增强术(MSA)。1年时MSA组96%反流得到控制,PPI组仅19%,MSA还改善生活质量、停用PPI并降低酸暴露,且无器械相关不良事件。

要点

  • MSA控制反流达96%,不受术前PPI反应影响。
  • 每日两次PPI仅19%反流得到控制。

核心结论

  • MSA在减少中重度反流方面优于每日两次PPI,且疗效维持12个月。

研究设计与样本

  • 随机试验纳入152例每日一次PPI仍中重度反流的GERD患者,随机分为每日两次PPI组(n=102)或腹腔镜MSA组(n=50),来自20个中心。

主要发现

  • MSA组及PPI交叉至MSA组共75例,72例(96%)反流得到控制。
  • 仅43例PPI组中8例(19%)报告反流控制。
  • MSA后61/75例(81%)GERD生活质量评分改善超过50%,68例(91%)停用每日PPI。
  • MSA后吞咽困难比例从15%降至7%(P < .005),腹胀从55%降至25%,食管酸暴露时间从10.7%降至1.3%(P < .001)。

关键数值与推荐

  • 反流控制:MSA组96%(72/75) vs PPI组19%(8/43)。
  • 生活质量改善超过50%:81%(61/75);停用每日PPI:91%(68/75)。
  • 吞咽困难从15%降至7%(P < .005);酸暴露时间从10.7%降至1.3%(P < .001)。

临床怎么用

  • 对于每日一次PPI仍中重度反流的GERD患者,可考虑MSA以控制反流并减少PPI使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Regurgitative gastroesophageal reflux disease (GERD) refractive to medical treatment is common and caused by mechanical failure of the anti-reflux barrier. We compared the effects of magnetic sphincter augmentation (MSA) with those of proton-pump inhibitors (PPIs) in a randomized trial. METHODS: Patients with moderate to severe regurgitation (assessed by the foregut symptom questionnaire) despite once-daily PPI therapy (n = 152) were randomly assigned to groups given twice-daily PPIs (n = 102) or laparoscopic MSA (n = 50) at 20 sites, from July 2015 through February 2017. Patients answered questions from the foregut-specific reflux disease questionnaire and GERD health-related quality of life survey about regurgitation, heartburn, dysphagia, bloating, diarrhea, flatulence, and medication use, at baseline and 6 and 12 months after treatment. Six months after PPI therapy, MSA was offered to patients with persistent moderate to severe regurgitation and excess reflux episodes during impedance or pH testing on medication. Regurgitation, foregut scores, esophageal acid exposure, and adverse events were evaluated at 1 year. RESULTS: Patients in the MSA group and those who crossed over to the MSA group after PPI therapy (n = 75) had similar outcomes. MSA resulted in control of regurgitation in 72/75 patients (96%); regurgitation control was independent of preoperative response to PPIs. Only 8/43 patients receiving PPIs (19%) reported control of regurgitation. Among the 75 patients who received MSA, 61 (81%) had improvements in GERD health-related quality of life improvement scores (greater than 50%) and 68 patients (91%) discontinued daily PPI use. Proportions of patients with dysphagia decreased from 15% to 7% (P < .005), bloating decreased from 55% to 25%, and esophageal acid exposure time decreased from 10.7% to 1.3% (P < .001) from study entry to 1-year after MSA (Combined P < .001). Seventy percent (48/69) of patients had pH normalization at study completion. MSA was not associated with any peri-operative events, device explants, erosions, or migrations. CONCLUSIONS: In a prospective study, we found MSA to reduce regurgitation in 95% of patients with moderate to severe regurgitation despite once-daily PPI therapy. MSA is superior to twice-daily PPIs therapy in reducing regurgitation. Relief of regurgitation is sustained over 12 months. ClinicalTrials.gov no: NCT02505945.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Bell R, Lipham J, Louie BE, et al. Magnetic Sphincter Augmentation Superior to Proton Pump Inhibitors for Regurgitation in a 1-Year Randomized Trial. Clin Gastroenterol Hepatol. 2019. PMID: 31518717. doi:10.1016/j.cgh.2019.08.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。